Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.
USARIEM, Natick, Massachusetts, United States
Fatima Memorial Hospital, Lahore, Punjab, Pakistan
General Hospital Lahore, Lahore, Punjab, Pakistan
Sir Gangaram Hospital, Lahore, Punjab, Pakistan
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
CHUV, Lausanne, Vaud, Switzerland
Istanbul University, Istanbul Faculty of Medicine, Department Orthopaedics and Traumatology, Istanbul, Çapa / Fatih, Turkey
Uppsala University Hospital, Uppsala, Sverige, Sweden
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
S. Nijalingappa Medical College, Bagalkot, Karnataka, India
Raichur Institute of Medical Sciences, Raichur, Karnataka, India
Sawai Man Singh Medical College, Jaipur, Rajasthan, India
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
Raichur Institute of Medical Sciences, Raichur, Karnataka, India
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.